ImmunityBio (IBRX) Return on Sales (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Return on Sales data on file, last reported at 0.14% in Q1 2026.

• Return on Sales for Q1 2026 came in at 0.14%, down 6.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.06% (up 7.0% YoY), and the FY2025 annual result was 0.03%, up 25.0% from the prior year.
• Return on Sales declined to 0.14% in Q1 2026 per IBRX's latest filing, from 0.02% in the prior quarter.
• Over five years, Return on Sales peaked at 0.02% in Q4 2025 and troughed at 73.57% in Q1 2022.
• A 5-year average of 13.27% and a median of 3.24% in 2023 frame the typical range for Return on Sales.
• The sharpest annual moves came in 2022 and 2023: Return on Sales plunged 6778 bps in 2022, then soared 7033 bps in 2023.
• A 5-year view of Return on Sales shows it stood at 14.84% in 2022, then dropped by 13 bps to 16.79% in 2023, then soared by 100 bps to 0.08% in 2024, then surged by 79 bps to 0.02% in 2025, then sank by 785 bps to 0.14% in 2026.
• Business Quant data shows IBRX's Return on Sales at 0.14% in Q1 2026, 0.02% in Q4 2025, and 0.02% in Q3 2025.